Navigating Share Purchase Agreements versus Asset Purchase Agreements in the HealthTech and MedTech Ecosystems

Why It Matters

The structure dictates post‑closing risk exposure, regulatory continuity, and tax efficiency, directly affecting valuation and integration speed in a highly regulated market.

Key Takeaways

• SPA preserves regulatory licences, avoiding re‑registration delays.
• APA isolates legacy liabilities, requiring extensive asset assignments.
• Data controller continuity in SPA reduces GDPR transfer risk.
• Tax efficiency differs: SPA enables CGT relief, APA grants allowances.
• TUPE triggers in APA, not in SPA, impacting employee transfers.

Pulse Analysis

The strategic choice between a share deal and an asset deal is more than a legal formality; it shapes a HealthTech company’s ability to maintain market access. Under an SPA, the legal manufacturer remains unchanged, allowing seamless continuation of MHRA licences and the UKCA transition window that runs through 2028‑2030. This continuity can be a decisive advantage when time‑to‑market is critical, especially for AI‑driven diagnostics that rely on existing approvals to generate revenue quickly.

Intellectual property and data considerations further tilt the balance. An SPA offers an unbroken chain of title for patents, software code, and AI models, simplifying licence enforcement and avoiding the need for multiple assignment deeds. Conversely, an APA demands meticulous IP assignment and triggers GDPR‑mandated data transfers, often requiring explicit patient consent for special‑category health data. From a tax perspective, sellers favor SPAs to tap into Business Asset Disposal Relief, reducing capital gains tax to roughly 10 %, while buyers may prefer APAs to claim fresh capital allowances on newly acquired hardware and intangible assets.

Practically, due‑diligence scopes diverge sharply. Share deals compel exhaustive corporate, employment, and compliance reviews because the buyer inherits all historic liabilities, including potential product‑defect claims under the Consumer Protection Act. Asset deals narrow the focus to identified assets but introduce complexities around TUPE, consent for third‑party contracts, and re‑registration of medical devices. Investors and counsel must weigh speed of integration against risk mitigation, aligning the deal structure with the company’s regulatory roadmap, IP portfolio, and tax optimisation goals.